1238324-73-6Relevant articles and documents
Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors
Demont, Emmanuel H.,Chung, Chun-Wa,Furze, Rebecca C.,Grandi, Paola,Michon, Anne-Marie,Wellaway, Chris,Barrett, Nathalie,Bridges, Angela M.,Craggs, Peter D.,Diallo, Hawa,Dixon, David P.,Douault, Clement,Emmons, Amanda J.,Jones, Emma J.,Karamshi, Bhumika V.,Locke, Kelly,Mitchell, Darren J.,Mouzon, Bernadette H.,Prinjha, Rab K.,Roberts, Andy D.,Sheppard, Robert J.,Watson, Robert J.,Bamborough, Paul
, p. 5649 - 5673 (2015)
Overexpression of ATAD2 (ATPase family, AAA domain containing 2) has been linked to disease severity and progression in a wide range of cancers, and is implicated in the regulation of several drivers of cancer growth. Little is known of the dependence of
SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
-
, (2020/12/11)
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors
Siu, Tony,Liang, Jun,Arruda, Jeannie,Li, Yiwei,Jones, Raymond E.,Defeo-Jones, Deborah,Barnett, Stanley F.,Robinson, Ronald G.
scheme or table, p. 4186 - 4190 (2009/04/07)
This paper describes the improvement of cell potency in a class of allosteric Akt 1 and 2 inhibitors. Key discoveries include identifying the solvent exposed region of the molecule and appending basic amines to enhance the physiochemical properties of the
